Off-Script and Under-Prescribed

How communities rescued a life-saving drug that medicine abandoned

Feb 03, 2026

At her son’s engagement party, Marcy faced the hardest moment: the toast. She was one of the first patients I prescribed naltrexone to, back when addiction treatment mostly meant recovery stories in church basements.

This is where she used to start bargaining. She would scan for a server, angle for a champagne flute, tell herself she “needed” it to get through the moment, then spend the rest of the night chasing the first sip.

This time, she stood up, raised her glass, and spoke. No craving. No inner negotiation. No fake performance. The champagne might as well have been water.

Marcy received her first dose of naltrexone in the late 1980s and still uses it only occasionally, when a rare craving surfaces.

That’s what naltrexone can do: it doesn’t just reduce drinking; it can remove the urgency that used to run the room.

So why, after several decades, is naltrexone just now getting traction in the addiction community? It is still under-prescribed, but the tide is finally changing.

The naltrexone story isn’t about its scientific discovery. It’s about adoption. A pill designed to save lives was itself kept alive by the very people it was meant to save.

If you’ve ever wondered why an FDA-approved, generic medication that reduces heavy drinking is still underused, this series is for you. This essay explains how adoption failed. Next, you’ll hear from the people who challenged the system and kept the medication alive.

What a pill can do

Marcy’s freedom wasn’t unique. In my first naltrexone study in the late 1980s, I heard the same puzzled reaction over and over. One subject, Jim, said it best: “That’s weird. I’ve never left a drink at the bar before.” He wasn’t celebrating sobriety. He was describing the absence of struggle.

These stories capture something clinicians rarely get to witness: a person with decades of daily drinking surprised by real freedom. Not the standard “success” story of abstinence through sheer force of will, white knuckles, constant vigilance, and a life engineered around avoiding risk. But rather, a life built around saying “yes” to new experiences, open to the wide range of joys that freedom offers.

What should have become standard care never did. A treatment that could turn obsessive craving into ease for many people was treated as optional. In contrast, the standard treatments were stuck in ways that were difficult and not particularly effective.

Off-script, the culture

When Dupont began to market naltrexone (ReVia) in 1995, company executives expected great things for the medication. Research showed it reduces craving, blunts alcohol’s reward, is non-addictive, and reduces relapse. It should have been part of routine care.

It didn’t.

Early prescribing stayed low. It was fairly simple to explain how naltrexone worked and to present data proving its efficacy. That wasn’t the problem. Rather, addiction treatment programs had a culture problem. Many systems were built around counseling-first approaches, abstinence-only expectations, and a moral narrative that viewed medication as “cheating.”

In plain English: the tool did not fit the tribe. It was too easy.

Plenty of abstinence-based programs have helped people. The mistake is treating them as the only legitimate path and quietly blocking evidence-based medication.

“I got sober without a pill. Why should my patients need one?”

“Alcoholism is a spiritual disease. How would a pill fix that?”

Those weren’t just opinions. They shaped what patients were offered, and what they were told counted as “real recovery.”

To be fair, culture wasn’t the only barrier.

Adoption is genuinely hard, even when everyone agrees in principle. Medications for alcohol addiction come with real-world challenges:

1. Many clinicians lack the training or confidence in prescribing.

2. Insurers often pay more for therapy hours than for medication management.

3. Patients avoid medications because of fear of stigma, side effects, or what the medication implies about their recovery.

4. Effects vary by person, and good results require consistent adherence and follow-through.

5. Naltrexone isn’t suitable for people actively using opioids.

Most of that is solvable. But ideology makes them invisible.

When a program’s culture treats medication as “not how we do things,” no one is motivated to solve adherence or training. The friction becomes an excuse not to use the medication rather than a motivation to change the system.

Guidelines don’t treat patients. Prescribing does.

Percy Menzies keeps hope alive: The Early Years.

Percy Menzies is the person in this story who refused to confuse “FDA-approved” with “adopted.” After naltrexone won FDA approval, DuPont launched ReVia and put Percy, a pharmacist by training, in charge of educating clinicians. I remember meeting him in those early years. We built a slide deck explaining how naltrexone worked and why it mattered. The reaction from much of the addiction treatment world was polite silence.

Doctors hesitated. Programs declined to offer it. Quite frankly, many patients were ambivalent about taking a medicine that blocked the joy from the one activity they craved the most.

So, Percy did what adopters do: he found ways to make naltrexone usable in the most difficult of settings. This included working with Lloyd Vacovsky at the Central Arizona Social Services homeless shelter. Naltrexone was given with directly observed therapy and paired with practical support. Research shows that naltrexone is most effective when combined with psychosocial support. This includes monitoring treatment outcomes and encouraging medication adherence.

Percy carried the same adherence logic into drug courts, where drug-court participants were closely monitored, encouraged to take naltrexone, and given access to psychosocial services to improve their level of functioning. We described naltrexone as one leg of a three-legged stool. The medication, behavioral, and social components made for a stable platform for recovery.

But these small success stories did not move the system. DuPont lost patent protection for naltrexone in 1995 but retained regulatory exclusivity for the alcohol indication through 1998. By 1999, with generics on the horizon, DuPont had little interest in promoting a medication that offered diminishing returns.

So, with little hope of making a difference from within the company, Percy left DuPont in 2000 and opened an evidence-based outpatient clinic in St. Louis to show that improved outcomes are not just abstract PowerPoint presentations. He calls the introduction of naltrexone a failed “penicillin moment”. The science arrived, but adoption needed a builder, not another peer-reviewed publication.

The academic script began to rewrite itself, but prescription rates didn’t follow suit.

In 1992, our group at Penn and Stephanie O’Malley’s group at Yale published the first randomized clinical trials of naltrexone’s efficacy. This launched a wave of other studies, growing the evidence base. These randomized trials, meta-analyses, and large reviews showed that, on balance, naltrexone improved drinking outcomes for many patients.

Then came Project COMBINE in 2006, the largest NIAAA-sponsored clinical trial. It was the turning point for the academic community. Patients received structured Medical Management and were assigned to naltrexone or placebo, and to acamprosate or placebo, with or without a Combined Behavioral Intervention (which included Cognitive Behavioral Therapy, Motivational Enhancement Therapy, and 12-Step Facilitation).

The results were clear: naltrexone but not acamprosate reduced heavy drinking when given in the context of Medical Management, which included supportive monitoring and adherence counseling. Adding specialized addiction therapies did not improve treatment outcomes for the naltrexone group with Medical Management. In fact, the group that had the worst outcomes received the combined specialized addiction therapies without supportive medical management or any pills.

No boutique program or daily meetings were required.

Guidelines followed. Professional societies endorsed it. The VA/DoD moved toward integrating it as standard care.

Then you look at what happened. Despite this evidence base, prescription rates remained strikingly low. Data from U.S. treatment facilities showed naltrexone use among alcohol use disorder admissions was only 0.53% in 2015, fewer than 1 in 200 patients.

Twenty years after the FDA approved naltrexone to treat alcohol addiction, it was still not prescribed to more than 99% of new admissions. This appalling statistic persisted even though the effect sizes for naltrexone are comparable to those of many medications for other chronic diseases. Imagine if cardiologists failed to recommend a statin for their patients with high cholesterol.

The academic script rewrote itself. The clinical script did not.

Why institutions resist

The naltrexone story is not unique. Medicine has seen this script before, and the HIV era is the clearest example. In the late 1980s, AZT showed up as the first real pharmacologic foothold against a lethal disease. It was imperfect, toxic, and contested, but it forced a blunt question: what counts as “good enough” when people are dying on schedule? Patient activists did not just protest. They became treatment-literate, argued about trial design and endpoints, tracked side effects, pushed for faster access, and built a parallel information network that moved faster than the official one. When more effective combinations arrived in the mid-1990s, the science did not magically “roll out.” Like naltrexone, it still needed pressure from an active grassroots movement that would not accept delay.

The same adoption gap shows up in a different context with conditions like chronic fatigue syndrome and long COVID. Here, the resistance is less moral and more of a problem for the standard medical model. Some disorders lack a clear physical basis; there is no single definitive test, no obvious lesion, no clean physical abnormality that shows on an MRI scan. So, the default move is dismissal, or the softer version, “we’re not sure it’s real.”

Meanwhile, patients are disabled, the evidence base slowly accumulates, and communities do what they always do when institutions stall: they compare notes, share what helps, warn each other about what harms, and push clinicians and researchers to take the lived phenotype seriously. Different diseases, same pattern: evidence arrives, the system hesitates, and patients build a workaround while pushing for medicine to catch up.

The spark wasn’t a journal article.

For many people, naltrexone was introduced not in a clinic, but from a TED talk.

Claudia Christian, an actress who publicly described her recovery using naltrexone and the Sinclair Method, gave a widely shared TEDx talk (currently at over 5 million views) that introduced many people to a different idea. Recovery from alcohol addiction doesn’t require confessing a character defect, and change doesn’t have to begin with abstinence. The talk didn’t replace science. It made the science clear and accessible.

This got things started. News about naltrexone and the Sinclair Method spread peer-to-peer. People with lived experience shared their stories in online forums, small coaching groups, and with informal mentoring. They compared notes on medication dosing, the critical role of medication adherence, and coping with side effects. Many people felt that, for the first time, their needs were addressed through a scientific rather than a moral approach.

From a method to a movement

A treatment doesn’t scale because it exists. It scales because someone builds the scaffolding around it. As we found in clinical research and Percy discovered while working with patients, the effectiveness of naltrexone improves when people are supported with tools to improve medication adherence, monitor outcomes, and address psychosocial issues.

That’s where programs like Thrive Alcohol Recovery come in. Thrive is a virtual program centered on naltrexone and the Sinclair Method, built to give people structure: education, tracking, and support that continues long after a prescription is written.

But the scaffolding didn’t only come from programs. It also came from peer-run platforms. For example, the subreddit r/Alcoholism_Medication and communities like TSM Meetups on Discord. In these peer-led communities, people compared notes, offered realistic expectations about dosing and side effects, and helped each other stay consistent.

Katie Lain helped bring that approach to a broader audience by turning scattered guidance into something closer to a repeatable process. Karen Dion helped professionalize the coaching layer, translating “take this pill before you drink” into the day-to-day behavior change work people actually need. And Steve Wagner, a moderator of r/Alcoholism_Medication and the TSM Meetups Discord, helped keep the peer-to-peer interactions usable by filtering noise, reinforcing adherence norms, and turning recurring questions into practical, searchable guidance.

Telemedicine turns the key.

Grassroots interest was real, but one barrier remained: someone still had to write the prescription. Many treatment programs and the general medical community had rarely used and forgotten about naltrexone. The Sinclair Warriors, as they called themselves on Facebook, hunted for practical access.

Then COVID hit, telemedicine expanded, and geography mattered less.

What followed was straightforward: if prescribers didn’t exist in your town, the internet made distance irrelevant. Telehealth platforms that understood AUD treatment moved in. Jonathan Hunt-Glassman at Oar Health is part of that shift: lowering the barriers to treatment by pairing medication access with coaching and follow-up. The result is not a new molecule. It’s the last mile of care. You didn’t need to confess your addiction in a waiting room. You didn’t need to find a specialist three states away. You could get evaluated, get prescribed, and get supported right from your kitchen table.

The script is changing

The system is finally moving, but slowly. National facility data show the share of U.S. counties with at least one treatment facility offering any medication for alcohol use disorder rose from 34% in 2017 to 44% in 2021.

It’s progress. It’s also a sad reminder that there is still a long way to go. Overall use of medications for alcohol use disorder remains very low, estimated at 1.9% of people with alcohol addiction in 2023. Rural and socioeconomically disadvantaged counties are even less likely to have access.

More recently, naltrexone has started showing up in settings that historically stayed hands-off, including emergency departments and other general medical settings. That is what it looks like when the script changes: not a press release, but a prescription written in the places people actually show up.

The storyteller, the skeptics, and the new audience

If you want an idea to spread, you need storytellers who can cross subcultures. Katie Herzog, a journalist, co-host of the Blocked and Reported podcast, and author of Drink Your Way Sober, helped carry the Sinclair Method and naltrexone from recovery circles into mainstream conversation. She brings her story to audiences who challenge institutions but don’t live in addiction forums. They aren’t looking for a new ideology; they want clear reporting and results they can trust.

What this story is really about

Here’s how we usually think of medical progress: researchers discover, institutions evaluate, patients benefit.

But for naltrexone, the story goes like this: researchers discover, institutions stall, patients build the workaround, and only then does the system start acting like it supported the idea all along.

What to do now

If you want fewer people dying while we wait for “the establishment” to catch up, don’t just fund research. Build adoption. That means:

• Normalize medication as ordinary care.

• Train clinicians to prescribe confidently.

• Design programs that provide psychosocial support to improve medication adherence and monitor treatment outcomes.

• Amplify the communities already sharing what works.

Because sometimes the people who save the treatment are the people it was supposed to save.

For clinicians: Are you prescribing naltrexone? Comment on what barriers exist in your setting: training, time, culture, reimbursement, or something else?

For patients and families: where did you first hear about medication options like naltrexone, and what kept you from getting access sooner?

Dr. Joe Volpicelli

Discussion about this post

Ready for more?